Trial Profile
Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction (EMMY-Trial) – a phase III Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2023
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Myocardial infarction
- Focus Biomarker; Therapeutic Use
- Acronyms EMMY-Trial
- 06 Oct 2023 Results of sub-group analysis assessing the effects of SGLT2i after acute myocardial infarction in people with and without type 2 diabetes, presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
- 29 Aug 2022 Primary endpoint N-terminal pro-hormone of brain natriuretic peptide (NT-proBNP) change over 26 weeks has been met according to results published in the European Heart Journal
- 29 Aug 2022 Results published in the European Heart Journal